Verastem Oncology Competitors and Similar CompaniesClear all
Verastem Oncology's competitors and similar companies include Tanvex BioPharma, Novartis, Mirati Therapeutics and InxMed.
 Verastem Oncology Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. |  Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Mirati Therapeutics Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer. |  InxMed InxMed (应世生物) is a clinical-stage biotechnology company that develops individualized medicines. | |
Founding Date | Founding Date 2010 | Founding Date 2013 | Founding Date 1996 | Founding Date 2013 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Private |
Tags | |||||
Locations | Locations Needham, US HQ Walsrode, DE | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations San Diego, US HQ Zug, CH | Locations HQ |
Employees | Employees 7328% increase | Employees 13827% decrease | Employees 75,883 | Employees 666% decrease | Employees 17 |
Financial | |||||
Revenue (est.) | Revenue (est.) $30.9m (FY, 2025) | Revenue (est.) NT$401m (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $12.4m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods NT$466.3m (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods $600k (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit (NT$10.6m) (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit $11.8m (FY, 2022) | Gross profit N/A |
Net income | Net income ($209.5m) (FY, 2025) | Net income (NT$1.5b) (FY, 2025) | Net income $14b (FY, 2025) | Net income ($740.9m) (FY, 2022) | Net income N/A |
Operating ⚠ | |||||
Phase I/II Trials Products | Phase I/II Trials Products 6 (FY, 2020) | Phase I/II Trials Products N/A | Phase I/II Trials Products 100 (FY, 2022) | Phase I/II Trials Products N/A | Phase I/II Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 170m | Total funding raised $ 346.9m | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 19m |
For sources of this data, please see the company profile
View Company Profiles
Tanvex BioPharma
HQ
Taipei, TW
Employees
138↓ 27% decrease
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyMirati Therapeutics
HQ
San Diego, US
Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer.
View companyInxMed
HQ
Employees
17
InxMed (应世生物) is a clinical-stage biotechnology company that develops individualized medicines.
View company